SB273005 is an integrin antagonist, primarily used in research settings to study cell adhesion and signaling pathways. It selectively inhibits αvβ3 and α5β1 integrins, which play key roles in angiogenesis, tumor progression, and metastasis. Due to this activity, SB273005 is widely applied in cancer research to evaluate the impact of integrin blockade on tumor cell migration, invasion, and survival. It has also been used in studies related to bone resorption, as integrins are involved in osteoclast function, making it a tool compound in osteoporosis-related research. Additionally, SB273005 helps investigate the role of integrins in inflammatory processes and vascular remodeling. Its application remains mainly confined to preclinical in vitro and in vivo models.